WordNet
- travel or traverse (a distance); "This car does 150 miles per hour"; "We did 6 miles on our hike every day"
- the syllable naming the first (tonic) note of any major scale in solmization (同)doh, ut
- proceed or get along; "How is she doing in her new job?"; "How are you making out in graduate school?"; "Hes come a long way" (同)fare, make_out, come, get along
- create or design, often in a certain way; "Do my room in blue"; "I did this piece in wood to express my love for the forest" (同)make
- carry on or function; "We could do with a little more help around here" (同)manage
- get (something) done; "I did my job" (同)perform
- treat with an agent; add (an agent) to; "The ray dosed the paint"
- the quantity of an active agent (substance or radiation) taken in or absorbed at any one time (同)dosage
- a measured portion of medicine taken at any one time (同)dosage
- recognize and respect (rights and beliefs of others); "We must tolerate the religions of others"
- have a tolerance for a poison or strong drug or pathogen or environmental condition; "The patient does not tolerate the anti-inflammatory drugs we gave him"
- the greatest or most complete or best possible; "maximal expansion"; "maximum pressure" (同)maximum
- to a maximal degree; "the cells maximally responsive to lines in this orientation will fire"
PrepTutorEJDIC
- 《疑問文・否定文を作る》 / 《否定命令文を作る》 / 《助動詞とbe動詞のどちらも含まない文に用いて付加疑問を作る》 / 《強意語として》 / 《文》《助動詞とbe動詞のどちらも含まない文に用いて倒置文を作る》 / 《あいづちを打つ場合に》 / 《先行する動詞またはそれを含む述部の代用》 / 《so,nor,neitherで始まる簡略文で》 / …‘を'『する』,行う,果たす / 《通例have done,時にbe doneの形で》…‘を'『終える』,済ませる / …‘を'作る,作り出す / …‘を'『処理する』,整える,片付ける / 〈学課〉‘を'『勉強する』,専攻する / 〈利益・害など〉‘を'与える,もたらす / 〈人〉‘に'『役立つ』,用が足りる(serve) / …の速度で進む,距離を行く / …‘を'見物する / 〈劇〉‘を'上演する;…‘の'役を演じる / …の役目(仕事)をする / 《おもに英》…‘を'だます,かつぐ / 《話》…をへとへとにさせる / 『する』;活動する / 《通例have done,時にbe doneの形で》(…を)『終える』,済ます《+『with』+『名』》 / 〈事が〉『運ぶ』;〈人が〉暮らしていく,健康である / 〈物が〉(…に)『間に合う』,十分である;〈人が〉(…に)役に立つ,向く《+『for』+『名』》 / 《複数形で》すべきこと / 〈C〉《おもに英》大宴会,大パーティー / 〈C〉《英話》詐欺,ぺてん
- ド(全音階の第1音)
- (おもに飲み薬1回分の)『服用量』 / (痛いこと・いやなことの)1回分,一定量 / (人などが受ける放射線の)線量 / 性病 / (…を)…‘に'投薬する,服用させる《+『名』+『with』+『名』》
- …‘に'『寛大な態度をとる』,‘を'黙認する / …‘を'『がまんする』,耐える / 〈薬品・毒物など〉‘に'耐性がある
- 最上限の,最高度の
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 治療抵抗性統合失調症 treatment resistant schizophrenia
- 2. 造血細胞移植のための前処置療法 preparative regimens for hematopoietic cell transplantation
- 3. 成人スティル病の治療 treatment of adult stills disease
- 4. 鎌状赤血球症に対するヒドロキシ尿素治療または疾患修飾療法 hydroxyurea and other disease modifying therapies in sickle cell disease
- 5. 社会不安障害の薬物療法 pharmacotherapy for social anxiety disorder
English Journal
- The use of nanoparticulate delivery systems in metronomic chemotherapy.
- Yu DH, Ban FQ, Zhao M, Lu Q, Lovell JF, Bai F, Wang C, Guan YY, Luan X, Liu YR, Fang C, Chen HZ.SourceDepartment of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China.
- Biomaterials.Biomaterials.2013 May;34(16):3925-37. doi: 10.1016/j.biomaterials.2013.02.017. Epub 2013 Mar 5.
- Metronomic chemotherapy aiming at inhibiting tumor angiogenesis with conventional chemotherapeutics is a promising strategy for antiangiogenic cancer therapy. However, current metronomic chemotherapy mainly focuses on free small-molecule drugs, without any effort to achieve tumor-specific biodistrib
- PMID 23465835
- Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
- Arjona Ferreira JC, Corry D, Mogensen CE, Sloan L, Xu L, Golm GT, Gonzalez EJ, Davies MJ, Kaufman KD, Goldstein BJ.SourceMerck Sharp & Dohme Corp., Whitehouse Station, NJ. Electronic address: juan_arjona@merck.com.
- American journal of kidney diseases : the official journal of the National Kidney Foundation.Am J Kidney Dis.2013 Apr;61(4):579-87. doi: 10.1053/j.ajkd.2012.11.043. Epub 2013 Jan 24.
- BACKGROUND: Treatment with oral antihyperglycemic agents has not been well characterized in patients with type 2 diabetes and end-stage renal disease (ESRD). The efficacy and safety of sitagliptin and glipizide monotherapy in patients with type 2 diabetes and ESRD on dialysis therapy were assessed i
- PMID 23352379
- Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.
- Pasquier E, Tuset MP, Street J, Sinnappan S, Mackenzie KL, Braguer D, Andre N, Kavallaris M.SourceChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, PO Box 81, Randwick, NSW, 2031, Australia.
- Angiogenesis.Angiogenesis.2013 Apr;16(2):373-86. doi: 10.1007/s10456-012-9321-x. Epub 2012 Nov 10.
- The anti-angiogenic activity of chemotherapy is both dose- and schedule-dependent. While conventional maximum tolerated dose (MTD) chemotherapy exerts only mild and reversible anti-angiogenic effects, low-dose metronomic (LDM) chemotherapy was developed to specifically target tumour angiogenesis. Ho
- PMID 23143659
Japanese Journal
- 新規抗悪性腫瘍薬S-1のマウスにおける免疫毒性作用 : S-1,UFTおよび5-FUとの比較試験
- 河内 泰英,前田 泰宏,森永 秀信 [他],大内田 昭信
- Journal of toxicological sciences 21(Supplement III), 691-701, 1996-11-27
- S-1の免疫毒性作用を類薬のUFTおよび5-FUと比較検討した。投与量はsarcoma 180を用いたマウスの効力試験(9日間)のMTDを最高に公比1.5で除した用量を設定した。すなわち, S-1が3.9,5.9,8.8および13.2 mg/kg/day,UFTが11.0,16.5,24.7および37.0 mg/kg/day, 5-FUが17.8,26.7および40.0 mg/kg/dayを用いた …
- NAID 110001805857
- ベンフレセートの毒性試験の概要
- 日本農薬学会誌 20(2), 229-237, 1995-05-20
- … Repeat dose studies in the rat, mouse and dog showed the material to be well tolerated with the maximally tolerated doses of 318, 561 and 400 mg/kg/day, respectively. … The liver was also a target organ at dose levels above the MTD in the rat and mouse as indicated by swelling of the periportal hepatocytes and centrilobular enlargement, respectively. …
- NAID 110001712814
- Failure of high dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: A murine study with clinical relevance?
- MARTIN D. S.
- J. Natil. Cancer Inst. 80, 496-501, 1988
- NAID 30024438835
Related Links
- Maximum tolerated dose (MTD) refers to the highest dose of a radiological or pharmacological treatment that will produce the desired effect without unacceptable toxicity. The purpose of administering MTD is to determine whether long-term ...
Related Pictures
★リンクテーブル★
| リンク元 | 「最大投与可能量」 |
| 関連記事 | 「tolerate」「do」「dose」「maximal」「tolerated」 |
「最大投与可能量」
「tolerate」
- v.
「do」
- v.
- する、行う
「dose」
- n.
「maximal」
- 最大の、極大の
「tolerated」
- adj.
- 許容的な、耐容性を示した
- poorly tolerated 認容性が低い